FDA Approval Licensing Protein Expression Treatment 
Drug Discovery World
SEPTEMBER 25, 2024
Figure 1: Major deals involving ADCs- 2024 Figure 2: Examples of FDA-approved ADCs – 2024 These include Johnson & Johnson’s $2 billion purchase of ADC specialist Ambrx in January, Genmab’s $1.8 billion buy of ProfoundBio in April, and Ipsen’s $900 million deal with Sutro for anticancer ADC STRO-003, also in April.
The Pharma Data
DECEMBER 8, 2020
Li stated, “One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. Pear’s reSET, reSET-O and Somryst are the first PDTs to receive FDA approval for treating disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 13, 2021
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Vivity received FDA approval in February 2020. provided an update on its ongoing NASH program.
The Pharma Data
NOVEMBER 26, 2020
(NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,
The Pharma Data
DECEMBER 29, 2020
(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,
Expert insights. Personalized for you.
162 
Let's personalize your content